Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the <scp>CYP3A4</scp> Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants

Alison Luckey(Global Antibiotic Research & Development Partnership), Jean-Yves Gillon(Drugs for Neglected Diseases Initiative), Kajal Larson(Entasis Therapeutics (United States)), John P. Mueller(Innoviva (United States)), Noha Rayad(PAREXEL International (United States)), Sophie Delhomme(Drugs for Neglected Diseases Initiative), M. Heep(Global Antibiotic Research & Development Partnership), Seamus O'Brien(Global Antibiotic Research & Development Partnership), Rainard Fuhr, John P O'Donnell(NKT Therapeutics (United States)), Gabrielle Kornmann(Global Antibiotic Research & Development Partnership)
Clinical and Translational Science
February 27, 2026
10.1111/cts.70515
Cited by 0

Related Papers

Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
|European Journal of Clinical Pharmacology|2024|28
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
|The Lancet|2025|26
2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study
|Open Forum Infectious Diseases|2023|25